NMN and NR Microdosing Protocols: What the Clinical Evidence Actually Shows

What "Microdosing" Means in the NAD Precursor Context

The term microdosing has no agreed clinical definition for NMN or NR. In psychedelic medicine, a microdose is typically 5 to 10% of a full pharmacological dose. Applied loosely to NAD precursors, practitioners who use the term generally mean doses of 100 to 150 mg/day, compared with the 250 to 1,000 mg/day range studied in trials.

That distinction matters, because every human outcome datum we have comes from doses at or above 250 mg/day. There is no published RCT testing 100 mg NMN or 100 mg NR as a primary intervention.

Why the Term Emerged Despite Thin Evidence

Dose-response data from animal models suggested that NAD+ repletion follows a roughly sigmoidal curve, with meaningful tissue NAD+ increases beginning at relatively modest oral doses. Yoshino et al. (Cell Metabolism, 2011) showed that 100 to 500 mg/kg NMN in mice restored NAD+ and reversed age-associated metabolic decline. Human pharmacokinetic extrapolation from those rodent data, adjusted for body surface area, landed some practitioners in the 100 to 200 mg range as an equivalent "physiological" dose. The pharmacokinetic logic is not unreasonable. The clinical outcome evidence does not yet exist to validate it.

The Supplement-vs-Drug Classification Problem

The FDA issued a draft guidance in 2022 proposing to exclude NMN from the dietary supplement category because it had been studied as a drug before being marketed as a supplement. That process remains unresolved as of early 2025. FDA draft guidance on NMN means practitioners and patients operate in a regulatory grey zone. NR (nicotinamide riboside) retains its GRAS-adjacent supplement status and is available without a prescription.

How Human Trials Actually Dosed NMN and NR

Published randomized controlled trials have tested a narrow band of doses. The table below summarizes the key studies.

Yoshino et al. (Science 2021): The Landmark NMN Trial

This is the most-cited human NMN efficacy study. Yoshino et al. (Science 2021, N=25) enrolled postmenopausal women with prediabetes or overweight, randomizing them to 250 mg/day oral NMN or placebo for 10 weeks.

Key results:

• Skeletal-muscle insulin signaling improved significantly in the NMN group, with increased expression of genes in the insulin-receptor substrate pathway.
• Whole-blood NAD+ metabolite concentrations rose in the NMN group relative to placebo.
• Body weight, fat mass, blood pressure, and fasting glucose did not differ significantly between groups.
• No serious adverse events were reported.

The authors wrote: "NMN supplementation for 10 weeks significantly increased the skeletal muscle insulin signaling and insulin sensitivity in postmenopausal women with prediabetes." That benefit appeared at exactly 250 mg/day. Whether 125 mg or 100 mg would produce the same result is untested.

NR Trials: Doses From 1,000 mg to 2,000 mg/Day

Elhassan et al. (Cell Reports 2019, N=12) gave healthy older men NR at 1,000 mg/day for 21 days. Skeletal-muscle NAD+ metabolome increased substantially, but no functional metabolic endpoints (insulin sensitivity, exercise capacity, body composition) changed significantly versus placebo.

Dollerup et al. (American Journal of Clinical Nutrition 2019, N=40) used NR at 2,000 mg/day for 12 weeks in obese men. Whole-blood NAD+ rose by approximately 50%, but again, no significant changes emerged in insulin sensitivity, body composition, or blood pressure versus placebo.

The pattern across NR trials at 1,000 to 2,000 mg/day is consistent: NAD+ goes up in blood; clinical endpoints mostly do not move. That dissociation between the biomarker and the outcome is one reason some researchers have proposed that tissue-specific delivery, not total circulating NAD+, drives outcomes.

Pharmacokinetic Data That Inform Lower Dosing

Trammell et al. (Nature Communications 2016) characterized the NR pharmacokinetic profile in humans. A single 1,000 mg oral NR dose raised plasma NR by roughly 60-fold over baseline within 2 to 3 hours, then returned to baseline by 8 hours. NAD+ in whole blood peaked at approximately 2.7-fold above baseline.

Dose-linearity data from that study and follow-on work suggest NAD+ rises are roughly proportional to dose in the 100 to 1,000 mg range, meaning a 250 mg dose produces approximately 25% of the NAD+ increment seen at 1,000 mg, and a 100 mg dose approximately 10%. Whether a 10% increment in circulating NAD+ translates to any tissue-level effect on aging pathways is not established in humans.

The Biological Rationale for Lower Doses

NAD+ Precursor Pathways and Saturation

NMN and NR both enter cells and are converted to NAD+ via distinct but overlapping enzymatic routes. Canto et al. (Cell Metabolism 2012) outlined the salvage pathway: NR is phosphorylated by NR kinases (NRK1/2) to NMN, then NMN is adenylylated by NMNAT enzymes to NAD+. The enzymes involved have saturable kinetics. At very high oral doses, precursor availability is no longer the rate-limiting step. At low doses, it may be.

This enzyme-saturation argument is the biological basis for the idea that smaller, more frequent doses could theoretically be more efficient than a single large dose. No human RCT has directly tested divided dosing versus bolus dosing against a clinical endpoint.

Sirtuin Activation Thresholds

SIRT1 and SIRT3, the NAD+-dependent deacetylases most linked to metabolic benefit, have reported Km values for NAD+ in the range of 100 to 300 µM. Basal intracellular NAD+ concentrations in human muscle are roughly 200 to 400 µM, declining with age. Camacho-Pereira et al. (Cell Metabolism 2016) showed that CD38, an NAD+ hydrolase upregulated with age and inflammation, is a primary driver of declining intracellular NAD+.

If the goal is to restore sirtuin activity, the required intracellular increment may be modest, perhaps 20 to 30% above the depleted aged baseline. Whether a 100 to 150 mg oral dose of NMN achieves that inside skeletal muscle or liver cells in humans is unknown.

Safety Profile Across Dose Ranges

Evidence From Trials at Standard Doses

Safety data from published trials up to 2,000 mg/day NR and 500 mg/day NMN are generally reassuring.

Martens et al. (Nature Aging 2023, N=30) examined NR at 1,000 mg/day for 6 weeks in older adults. Liver function tests, complete blood counts, and metabolic panels remained within normal limits. The most common adverse events were mild nausea and GI discomfort, reported in approximately 20% of participants on active drug versus 12% on placebo.

No published trial has identified a serious adverse event attributable to NMN or NR at any dose tested in humans as of early 2025.

What the Safety Data Do Not Tell Us

All published human RCTs ran for 10 to 12 weeks or less. Long-term safety data at any dose, including low doses, are absent. Theoretical concerns include:

• CD38 substrate competition. Excess NAD+ precursor loading could theoretically shift CD38 activity in ways that affect immune cell function. No human trial has detected this.
• Methylation burden. NAD+ is catabolized partly via methylnicotinamide, consuming S-adenosylmethionine (SAM). High-dose supplementation over months could theoretically affect methylation capacity in individuals with MTHFR variants. Kraus et al. (eLife 2014) discussed this pathway.
• Cancer biology uncertainty. NAD+ is consumed by PARP enzymes in DNA repair and by sirtuins. Some cancer cells upregulate NAD+ synthesis. No human trial has reported increased cancer incidence, but trials are far too short to detect this signal.

At microdoses of 100 to 150 mg/day, the methylation burden and CD38 concerns are proportionally smaller. But the absence of harm at higher doses for 10 to 12 weeks does not confirm safety at lower doses over years.

Practical Microdosing Frameworks Used in Clinical Practice

No published guideline from the Endocrine Society, ADA, AACE, or any major body recommends NMN or NR supplementation at any dose. The following represents the clinical reasoning some longevity-focused physicians apply when patients request guidance on lower-dose protocols. It is not an endorsed standard of care.

Framework 1: Biomarker-Titrated Low Dosing

1. Obtain a baseline whole-blood or PBMC NAD+ level using a validated commercial assay (e.g., Jinfiniti Precision Medicine NAD+ test or equivalent).
2. Start at 125 to 250 mg/day NMN or NR, taken in the morning with food to reduce GI symptoms.
3. Retest whole-blood NAD+ at 4 to 6 weeks. Target a 30 to 50% increase from baseline, which aligns roughly with the increments seen at 250 mg in the Yoshino trial.
4. If the 30 to 50% target is not met and tolerability is good, increase to 250 to 500 mg/day and retest at another 4 to 6 weeks.
5. If baseline NAD+ is already in the upper quartile for age-matched reference ranges, the incremental benefit of supplementation is uncertain. Watchful waiting may be the more defensible position.

This approach treats NAD+ as a surrogate endpoint, not a validated clinical biomarker. No trial has shown that achieving a specific NAD+ target improves longevity outcomes in humans.

Framework 2: Fixed Low-Dose Protocol With Metabolic Monitoring

Some practitioners simply start patients at 250 mg/day (the lowest dose with an efficacy signal) and monitor fasting glucose, HOMA-IR, and triglycerides at baseline and 12 weeks. This mirrors the Yoshino study design closely and gives the best chance of detecting the insulin-sensitivity signal that study identified.

Choosing 100 to 150 mg/day instead reduces cost and theoretical risk, but also moves further from the evidence base.

Timing and Delivery Considerations

The Yoshino trial dosed NMN once daily in the morning. Animal data from Mills et al. (Cell Metabolism 2016) suggested that oral NMN reaches tissues within 15 to 30 minutes in mice, a finding that has not been replicated in comparable human pharmacokinetic studies. Taking NMN or NR with food appears to reduce nausea without significantly affecting NAD+ increments based on available tolerability data, though a dedicated food-effect PK study in humans has not been published.

Sublingual and liposomal NMN formulations are marketed with claims of superior bioavailability. No peer-reviewed head-to-head PK trial comparing these formulations to standard oral capsules exists as of early 2025.

Who Might Reasonably Consider Lower-Dose Protocols

Given the evidence gap, the patients most likely to gain something from a cautious lower-dose approach are those for whom standard doses cause GI intolerance. Starting at 125 to 250 mg/day and titrating up based on tolerability and biomarker response is physiologically coherent, even if clinical outcome validation is absent.

Patients with postmenopausal status, insulin resistance, or prediabetes have the strongest mechanistic reason to consider supplementation at the doses studied in trials, based on the Yoshino (Science 2021) data. For these patients, starting below 250 mg/day prolongs the time before reaching the dose with any evidence of benefit.

Healthy adults with no metabolic risk factors have essentially no RCT evidence to guide NMN or NR use at any dose. The National Institute on Aging's Interventions Testing Program is ongoing, but has not yet published NMN longevity data in humans.

What Future Research Would Need to Show

For a microdosing protocol to be evidence-based rather than evidence-adjacent, the field needs:

1. A dose-finding RCT with at least three arms (e.g., 100 mg, 250 mg, and 500 mg NMN) against a placebo, powered for insulin sensitivity or another validated metabolic endpoint, with duration of at least 12 weeks.
2. Tissue biopsy or MRS-based intramuscular NAD+ measurement to confirm that low doses actually reach and alter NAD+ in target tissues, not just in blood.
3. Long-term safety data, at minimum 52 weeks, with attention to methylation markers and immune parameters.

The ClinicalTrials.gov registry lists several ongoing NMN trials as of early 2025, including investigations in cardiac function and cognitive aging, but none are specifically powered to compare doses below 250 mg/day against standard doses.

Current Evidence Summary by Dose Range

| Dose Range | Molecules Tested | Human RCT Evidence | NAD+ Signal | Clinical Outcome Signal | |---|---|---|---|---| | <250 mg/day | None formally | None | Extrapolated only | None | | 250 mg/day | NMN | Yoshino 2021 (N=25) | Yes | Insulin sensitivity (muscle) | | 500 to 1,000 mg/day | NMN, NR | Multiple small RCTs | Yes | Inconsistent | | 1,000 to 2,000 mg/day | NR | Dollerup 2019 (N=40); Elhassan 2019 (N=12) | Yes | Minimal to none |

The dose-response curve for clinical benefit does not appear to be monotonically increasing. Higher NAD+ in blood does not reliably produce better outcomes. This makes a strong argument against simply maximizing dose. It does not, by itself, make a strong argument for doses below 250 mg/day.